6 completed, 1 not yet recruiting. 5 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 4, Not yet recruiting 1 |
| Phase 2 | 2 | Completed 2 |
Follow DWP450: new trials by email Literature Review of DWP450 trials Research Report on DWP450
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of DWP450 in Japanese Subjects With Glabellar Lines DWP450 20 U, 0.9% Saline Solution 0.5 mL - Glabellar Lines | Phase 3 | Not yet recruiting | Daewoong Pharmaceutical Co. LTD. | 120 | 2027-01-01 | 2026-08-26 |
| DWP450 for Treating Moderate to Severe Glabellar Lines DWP450, Botox® - Moderate to Severe Glabellar Lines | Phase 3 | Completed | Daewoong Pharmaceutical Co. LTD. | 473 | 2020-08-12 | 2024-04-09 |
| Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy DWP450, Placebo - Benign Masseteric Hypertrophy | Phase 3 | Completed | Daewoong Pharmaceutical Co. LTD. | 180 | 2020-03-04 | 2022-11-30 |
| Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006 DWP-450 (Botulinum purified neurotoxin, Type A) - Glabellar Frown Lines | Phase 2 | Completed | Evolus, Inc. | 570 | 2015-05-01 | 2019-04-24 |
| A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001 Botulinum toxin, Type A, 0.9% sterile, unpreserved saline - Glabellar Frown Lines | Phase 3 | Completed | Evolus, Inc. | 330 | 2015-01-01 | 2019-03-27 |
| A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002 Botulinum toxin, Type A, 0.9% sterile, unpreserved saline - Glabellar Frown Lines | Phase 3 | Completed | Evolus, Inc. | 324 | 2015-01-01 | 2019-03-27 |
| Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines Botulinum purified neurotoxin, Type A - Glabellar Frown Lines | Phase 2 | Completed | Evolus, Inc. | 352 | 2014-08-01 | 2019-04-24 |
Evolus, Inc. (4) · Daewoong Pharmaceutical Co. LTD. (3)
United States (4) · China (1) · South Korea (1)
Rui Avelar, MD (4)